Is the treatment of inflammatory arthritis different in sickle cell disease?

dc.contributor.authorKimyon, Gezmis
dc.contributor.authorIlhan, Gul
dc.date.accessioned2024-09-18T20:02:39Z
dc.date.available2024-09-18T20:02:39Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground/aim: Musculoskeletal findings are common in sickle cell patients and may be confused with inflammatory arthritis. In addition, complications such as frequent infections may create difficulties while choosing drugs such as steroids, methotrexate, or anti-TNFs. Our aim is to reveal whether the treatment is different in sickle cell patients with rheumatic diseases such as rheumatoid arthritis. Materials and methods: Patients followed by Rheumatology and Hematology divisions of Hatay Mustafa Kemal University Hospital were retrospectively screened. Excluding patients with musculoskeletal findings associated with sickle cell disease (SCD), patients with chronic or acute inflammatory arthritis were enrolled into study. Demographic data, disease activities, the drugs used, frequency of infection, and sickle cell-related crisis before and after rheumatic disease diagnosis-treatment of the patients were examined. Results: Inflammatory rheumatic disease was detected in 14 of 28 sickle cell patients evaluated in the rheumatology department for musculoskeletal complaints. Twelve of the patients were female and 2 were male. The median duration of rheumatic disease was 27 months (16.5). Eight of these patients had rheumatoid arthritis, 1 had ankylosing spondylitis, reactive arthritis, gout, connective tissue disease, undifferentiated monoarthritis, and 1 patient had undifferentiated oligoarthritis. For rheumatic disease, 11 (78.6%) of the patients were using steroids, 8 (57.1%) hydroxychloroquine, 4 (28.6%) methotrexate and sulfasalazine, 2 (14.3%) leflunomide, 1 (7.1%) anti-TNF (etanercept), and 1 allopurinol and colchicine. The frequency of SCD-related crisis and annual serious infections before and after rheumatic disease treatment were similar (p = 0.31). Conclusion: The clinical manifestations of inflammatory arthritis such as rheumatoid arthritis and sickle cell disease may overlap. The use of drugs such as steroids, methotrexate, or anti-TNF in sickle cell patients with rheumatic disease is the same as in patients without sickle cell disease. However, treatment should be individualized in patients with complications such as infection.en_US
dc.identifier.doi10.55730/1300-0144.5515
dc.identifier.endpage1728en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue5en_US
dc.identifier.pmid36422487en_US
dc.identifier.scopus2-s2.0-85140297547en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1721en_US
dc.identifier.trdizinid1145281en_US
dc.identifier.urihttps://doi.org/10.55730/1300-0144.5515
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1145281
dc.identifier.urihttps://hdl.handle.net/20.500.12483/7940
dc.identifier.volume52en_US
dc.identifier.wosWOS:000890907200035en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectArthritisen_US
dc.subjectsickle cell diseaseen_US
dc.subjectsteroiden_US
dc.subjectmethotrexateen_US
dc.subjectanti-TNFen_US
dc.titleIs the treatment of inflammatory arthritis different in sickle cell disease?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Tam Metin / Full text
Boyut:
104.02 KB
Biçim:
Adobe Portable Document Format